Life Line Screening Offers Blood Test That May Provide Early Insight Into Alzheimer’s Disease Risk

A simple blood test that measures an Alzheimer’s-related biomarker may help adults 55 and older decide whether further evaluation is appropriate, even before symptoms appear

INDEPENDENCE, Ohio, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Life Line Screening, a national leader in preventive health screenings, today announced the availability of a new blood test that may help people better understand their risk for Alzheimer’s disease. The test measures a biomarker in the blood called phosphorylated tau 217, or p-tau217. Higher levels of p-tau217 can be associated with changes in the brain related to Alzheimer’s disease, even before noticeable problems with memory or thinking begin. Research has shown that, among older adults without signs of cognitive impairment, higher p-tau217 levels may be associated with a greater risk of developing cognitive problems in the future.

According to the National Institute on Aging, Alzheimer’s disease-related biological changes may begin 10-20 years before noticeable memory or cognitive problems emerge. To expand access to early information about these changes, Life Line Screening is offering the p-tau217 blood test to adults 55 and older in convenient community settings nationwide. The test may help individuals and their physicians determine whether further evaluation is appropriate.

“For more than 30 years, Life Line Screening has helped people identify potential health risks earlier,” said Matt Miller, CEO of Life Line Screening. “In just the past few years, treatment options for Alzheimer’s disease have expanded significantly, making earlier awareness more important than ever. By increasing access to Alzheimer’s-related biomarker testing, we want to give people information that can help them have more informed conversations with their healthcare providers and better understand what steps may be available to them.”

The p-tau217 blood test does not diagnose Alzheimer’s disease since it does not provide the required clinical and neurologic evaluation. However, the test can provide important information for individuals to discuss with their physicians along with evidence-based steps to promote cognitive and overall health. Dr. Todd Levine, a leading neurologist and researcher in early detection of neurodegenerative diseases, supports Life Line Screening offering the blood test, stating “Brain health begins long before symptoms appear. The greatest opportunity to change your future is to act before your brain asks for help.”

“We’ve made the process as simple and accessible as possible,” added Jim Waters, COO of Life Line Screening. “It requires a standard blood draw with no imaging or spinal tap required. Participants can attend a Life Line Screening event in their community, have their blood drawn and receive results. There’s no physician referral. It’s about bringing access to important information closer to where people live.”

About Life Line Screening

Life Line Screening is a national preventative health company that has performed more than 11 million screenings since 1993. The company delivers affordable, convenient health screenings directly into communities, helping adults identify cardiovascular, stroke, and other serious health risks before symptoms appear. Life Line Screening’s mission is to give every adult the information they need to take control of their health and live a longer, more active life. Learn more at lifelinescreening.com.

The p-tau217 blood test is a lab-developed test developed by Quanterix Corporation consistent with CLIA standards. It is not FDA-cleared, which is typical for lab-developed tests. Results are not diagnostic and are intended to support, replace evaluation by a licensed physician. Available to adults ages 55 and older at select locations.

Media Contact: Michaelann.Cartwright@llsa.com